Immunicon — Investor Presentation (November 2006)
26 slides from Immunicon's investor presentation, Nov 2, 2006
Slide 1: Management Presentation November 2006
Management Presentation November 2006 Cellular Information for Better Healthcare Circulating Tumor Cells Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management ’ s current views and opinions as to the status of the Company ’ s products, clinical trials, regulatory approval process, product development, research programs and other future events and op
Slide 3: Immunicon Value Proposition
Immunicon Value Proposition Immunicon develops and commercializes proprietary cell- and molecular-based human diagnostic and life science research products Cancer products sold through Veridex, a Johnson & Johnson company – Received FDA clearances for our instruments and CellSearch™ Circulating Tumo
Slide 4: CellTracks Products for Cellular Analysis
CellTracks ® Products for Cellular Analysis Circulating Tumor Cell Kit Sample Collection and Preservation Standardized Rare Cell Capture Endothelial Cell Kit Sample Analysis Kits for Cell Counting
Slide 5: CellTracks Products: CEC Kit, Profile Kit
CEC Kit Profile Kit CellTracks ® Products Marker Reagents for Characterization for Targeted Therapy * HER-2/neu * EGFr * IGF-1R * bcl-2 * M30 * other candidates with Pharma Enrichment Kits for Downstream Molecular Analysis FISH in cartridge (in development) Cancer Confirmation Gene Amplification Hea
Slide 6: CTCs as a "Real-Time Biopsy"
CTCs as a “ Real-Time Biopsy ” Blood Test Most tumors are of epithelial cell origin: Isolation of epithelial cells may mean pan - carcinoma capability Count Phenotype & Genotype Assess Prognosis Direct Therapy Monitor Disease Diagnose Specify Therapy Circulating Tumor Cells (CTCs) and Associated Mar
Slide 7: Circulating Tumor Cells Predict Survival
Circulating Tumor Cells Predict Survival Time from Baseline (Months) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Logrank p < 0.0001 21.9 Months 10.9 Months > 5 CTCs n=87 (49%) <5 CTCs n=90 (51%) NEJM 2004, ASCO 2004 / 2005 Before initiation of therapy
Slide 8: Change in CTCs Predict Survival
Change in CTCs Predict Survival Package Insert, October 2005 Clinical Cancer Research, July 2006 green vs. red p=0.0001 green vs. blue p=0.3188 green vs. orange p=0.0014 blue vs. red p=0.0002 22.6 mo. 19.8 mo. 10.6 mo. 4.1 mo. Time from Baseline (months) < 5 CTCs at First and Last Draw 83 (47%) >5 C
Slide 9: Any CTCs Impact Survival: Treat to Zero!
Any CTCs Impact Survival: Treat to Zero! CTC / 7.5 ml blood Median 95% Low limit 95% Upper limit 29% 71% 61% 56% 51% 48% 45% 43% 43% 40% 36% =0 >1 >2 >3 >5 >7 >8 >9 >6 >4 >10 Median 95% Low limit 95% Upper limit =0 >1 >2 >3 >5 >7 >8 >9 >6 >4 >10 223 patients San Antonio Breast Cancer Symposium 2005
Slide 10: A New Standard for Cancer Disease Management
A New Standard for Cancer Disease Management Future standard: Number, protein expression, and/or gene expression of CTCs better reflects efficacy of treatment Current standard: Radiologist measures changes in lesions on a CT scan to assess tumor burden increase/decrease Objective, quantitative 3-4 w
Slide 11: CTC versus CT Scans to Predict Survival
CT Scans 11.9 +5.7 weeks *Centralized Review by Two Independent Radiologist. Third Radiologist was used in cases of disagreement (11%) CTC versus CT Scans to Predict Survival CCR in press / ASCO 2005 23.8 Months 6.4 Months S/PR & <5CTCs n=84 (61%) PD & <5CTCs n=20 (14%) S/PR & >5CTCs n=12 (9%) PD &
Slide 12: Personalized Medicine: Her2 and targeted therapy selection
Her2 - Her2 + Her2 ++ Her2 +++ Time (weeks) Taxol Herceptin Int J Oncol 21: 1111-1118, 2002 “Personalized Medicine” Enables selection of targeted therapies
Slide 13: Cancer Confirmatory Test
Leukocyte Tumor Cell Cancer Confirmatory Test Chromosome 1 Chromosome 7 Chromosome 8 2 x1, 2 x 7, 2 x 8 3 x1, 5 x 7, 4 x 8
Slide 14: Assessment of Treatment Targets on CTCs
PNAS , 101: 9393-9398, Cytokeratin Her-2 Her-2 protein CEP 17 Her-2 gene CEP 17 / Her-2 gene 1+: 1.0 3+: 3.5 2+: 1.7 Assessment of Treatment Targets on CTCs
Slide 15: Significant Clinical Utility of Circulating Tumor Cells
Significant Clinical Utility of Circulating Tumor Cells Patient Management Early evidence of treatment failure: gives the oncologist information to change therapy within weeks Predictive at any time point during treatment CTCs predict survival time in patients undergoing chemo & hormonal therapy CTC
Slide 16: Advanced Technology for Simple Cell Counting
Instrument Rapid, accurate automated counts Simple to use 2-color analysis Uses proven technology Kits Simple cell counting (ViaSure) Immunomagnetic - Selection (IMS) Isolate and count specific cells Advanced Technology for Simple Cell Counting
Slide 17: Research and Clinical Development Programs
Research and Clinical Development Programs Colorectal cancer – endpoints achieved! Prostate cancer: 2Q07 FDA submission on 200 patient study Research studies – CTCs in early stage breast cancer and colorectal cancer – Impact on survival of changing therapy based on CTCs (SWOG) Develop FISH technolog
Slide 18: Success in Pivotal Clinical Trial in Metastatic Colorectal Cancer
Success in Pivotal Clinical Trial in Metastatic Colorectal Cancer Primary and secondary endpoints were achieved – Primary – agreement with imaging – Secondary - predict progression-free survival and overall survival. Large, multi-center trial – 481 patients; 55 sites in US and Europe Anticipate late
Slide 19: Product Commercialization
Product Commercialization Oncologists Pathologists/laboratories Pharma Services Molecular Diagnostics Products and Services Life Science Research Instruments and Kits Infectious Disease Diagnostics
Slide 20: Summary of instrument shipments and sales
Summary of instrument shipments and sales Year ended Six months end Three months end Cumulative @ June 30, 2006 Instrument shipments CellTracks Analyzer II CellSpotter (6) - Total Analyzers CellTracks AutoPreps Instruments sold (1) Total CellTracks Analyzer II Total CellSpotter - Total Analyzers Tot
Slide 21: System Placements, by Customer/Geography
System Placements, by Customer/Geography Third party: 54.5 Total Placements: 75 CellTracks Analyzer II Upgrade 7.5 1.0 1.0 5.5 Veridex internal use Pharma/CRO Reference Lab 35.5 19.5 Hospital/Practice Total Shipments Total Japan/ Asia EU USA As of 9/30/06
Slide 22: Financial Status
Financial Status Cash burn guidance for 2006 - $20 to $22 million Headcount at September 30, 2006 = 106 Borrowing capacity of $12.0 million @ =9/30/06 September 30, 2006 December 31, 2005 Cash and cash equivalents 29,535 $ 44,098 $ 9 months ended 9/30/06 9 months ended 9/30/05 Product & service reve
Slide 23: Milestones Achieved
Milestones Achieved Publications in major journals ( NEJM, CCR, JCO) U.S. in vitro diagnostic (IVD) launch 3Q04 510(k) clearance of expanded data Oct. 2005 Trial in colorectal cancer – endpoints met Sep. 2006 Trial in prostate cancer enrollment complete Jan. 2006 Kreatech license agreement for FISH
Slide 24: Upcoming Milestones/Presentations
Upcoming Milestones/Presentations Colorectal cancer 510(k)indication 1H07 Prostate cancer 510(k)indication 3Q07 Scientific meetings – CHI Clinical Trial Workshop Nov. 2006 – San Antonio Breast Cancer Symposium Dec. 2006 – Cell Biology Conference Dec. 2006 – Molecular Tri-Conference Workshop Feb. 200
Slide 25: Immunicon Value Proposition
Immunicon Value Proposition Immunicon develops and commercializes proprietary cell- and molecular-based human diagnostic and life science research products Cancer products sold through Veridex, a Johnson & Johnson company – Received FDA clearances for our instruments and CellSearch™ Circulating Tumo
Slide 26: Contact Information
Contact Information Masons Mill Road, Suite Huntingdon Valley, Pennsylvania phone 215.830.0777 fax 215.830.0751 web www.immunicon.com